Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (LIVN)
NASDAQ:LIVN
LIVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$32.48 - $58.42
Previous CloseN/A
Volume66.13K
Average Volume (3M)760.65K
Market Cap
$3.17B
Enterprise Value$2.35B
Total Cash (Recent Filing)$593.64M
Total Debt (Recent Filing)$473.40M
Price to Earnings (P/E)30.6
Beta0.90
Next Earnings
Oct 29, 2025EPS Estimate
0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.05
Shares Outstanding54,601,074
10 Day Avg. Volume669,684
30 Day Avg. Volume760,650
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit2.60
Enterprise Value/Ebitda-32.14
Forecast
1Y Price Target
$79.29Price Target Upside35.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLIVN's 2Q25 revenue and EPS beat consensus.
Market GrowthLivaNova received approval for Essenz in China, its second-largest market by install base, and will begin commercialization.
Product DevelopmentLIVN has submitted for premarket approval of its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea.
Bears Say
Market RiskThe setup for new patients in US epilepsy, with 1Q guide adjusted slightly downward, poses a risk.
Operational ChallengesLIVN's US Epilepsy business experienced procedure deferrals due to a voluntary field service notification, causing a financial impact.
Valuation ConcernsA recent downgrade to Peer Perform after a multi-year stint with a positive rating indicates concerns about the stock's valuation and potential risks.
LivaNova News
LIVN FAQ
What was LivaNova PLC’s price range in the past 12 months?
LivaNova PLC lowest stock price was $32.48 and its highest was $58.42 in the past 12 months.
What is LivaNova PLC’s market cap?
LivaNova PLC’s market cap is $3.17B.
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is Oct 29, 2025 which is in 49 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on Aug 06, 2025. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.867 by $0.183.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is 0.92.
How many shares outstanding does LivaNova PLC have?
LivaNova PLC has 54,601,074 shares outstanding.
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of $1.05 in its last earnings report, beating expectations of $0.867. Following the earnings report the stock price went up 11.148%.
Which hedge fund is a major shareholder of LivaNova PLC?
Currently, no hedge funds are holding shares in LIVN
LivaNova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.29 (35.96% Upside)
$79.29 (35.96% Upside)
Blogger Sentiment
Bullish
LIVN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 119.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $84.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 11.9%
Last 30 Days ▲ 11.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.92%
12-Months-Change
Fundamentals
Return on Equity
-17.87%
Trailing 12-Months
Asset Growth
2.18%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
LIVN Company Deck
LIVN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance for LivaNova in the second quarter of 2025, with significant revenue growth, successful clinical milestones, and improved financial health. However, supply chain constraints and an increased tax rate were noted as challenges.View all LIVN earnings summariesLIVN Stock 12 Month Forecast
Average Price Target
$79.29
▲(35.96% Upside)
Technical Analysis
Integra Lifesciences
―
Ufp Technologies
―
TransMedics Group
―
Cytek Biosciences
―
PROCEPT BioRobotics
―
Ownership Overview
0.28% Insiders
31.65% Mutual Funds
29.72% Other Institutional Investors
18.66% Public Companies and
Individual Investors